Discussion
Diagnosis With Brief Discussion
- Diagnosis
- MDA-5 associated ILD
- Radiologic Findings
- Figs. 1–3. Initial chest radiographs demonstrated subpleural reticulation and patchy consolidations with lower lobe predominance, and chest CT revealed peribronchial and subpleural consolidations.
Figs. 4–5. Follow-up chest CT obtained 2 weeks later showed increased extent of consolidations and ground-glass opacities.
Figs. 6–7. Follow-up chest CT at 4 weeks demonstrated further progression of consolidations and ground-glass opacities, with newly developed pneumomediastinum.
- Brief Review
- The patient presented with dyspnea and had no significant past medical history. Chest CT demonstrated an organizing pneumonia pattern, for which steroid therapy was initiated; however, subsequent imaging showed progression of pulmonary abnormalities in conjunction with clinical deterioration. Antinuclear antibody testing revealed a titer of 1:160, and a palmar rash was noted. Additional serologic evaluation demonstrated positivity for anti–MDA-5 antibody.
Anti–melanoma differentiation–associated gene 5 (MDA-5) antibody–positive disease represents a distinct subset of dermatomyositis, most commonly associated with clinically amyopathic dermatomyositis (CADM) and a high risk of rapidly progressive interstitial lung disease (RP-ILD). Patients typically exhibit minimal or absent muscle weakness with normal or mildly elevated creatine kinase levels, while characteristic cutaneous manifestations—such as painful digital ulcerations, palmar papules, and Gottron’s papules—are prominent. This phenotype is reported more frequently in East Asian populations and is associated with a particularly aggressive pulmonary course.
Pulmonary involvement is the major determinant of prognosis in anti–MDA-5–positive patients. High-resolution computed tomography commonly demonstrates bilateral ground-glass opacities and consolidations with peribronchovascular or subpleural distribution, often showing a mixed pattern of nonspecific interstitial pneumonia and organizing pneumonia. Disease progression may occur over weeks to months, frequently leading to respiratory failure despite intensive immunosuppressive therapy. Elevated serum ferritin levels have been consistently associated with disease activity and poor outcomes, underscoring the importance of early recognition and prompt initiation of combination immunosuppressive treatment.
- References
- 1. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kDa polypeptide, CADM-140, in patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571–1576.
2. Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti–MDA-5 antibody testing for predicting rapidly progressive interstitial lung disease in dermatomyositis. Rheumatology (Oxford). 2012;51(7):1278–1285.
3. Tsuji H, Nakashima R, Hosono Y, et al. Multidisciplinary treatment for anti–MDA-5 antibody–positive dermatomyositis with rapidly progressive interstitial lung disease. Arthritis Rheumatol. 2020;72(3):488–498.
- Keywords